Skip to main content
Clinical Trials/NCT06021405
NCT06021405WithdrawnNot Applicable

A Prospective Study to Investigate the Pathophysiology of the Koebner's Phenomenon in Psoriasis and Lichen Planus

Marie-Charlotte Brüggen0 sites70 target enrollmentStarted: September 1, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Withdrawn
Sponsor
Enrollment
70
Primary Endpoint
Differences in the transcriptomic profile comparing psoriasis patients with and without induced koebner phenomenon

Study Overview

Brief Summary

Psoriasis and lichen planus often occur at mechanically irritated skin sites (e.g. tight clothing). The investigators would like to investigate this phenomenon in more detail in this study. For this purpose, the skin is specifically irritated at a small and cosmetically favorable site by tearing off scotch tape or rubbing with a wooden spatula. In order to be able to examine the inflammatory processes caused by the irritation more closely, a small skin sample and a skin swab are taken from the irritated area. This skin sample and the swab are repeated after three and fourteen days.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Basic Science
Masking
None

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Dermatologist diagnosed psoriasis (group psoriasis), lichen planus (group lichen planus) or no skin disease (group healthy controls)
  • •Subject is capable of giving informed consent
  • •Signed informed consent

Exclusion Criteria

  • •Use of systemic immunosuppressive/immunmodulating agents in the last three months
  • •Use of topical anti-inflammatory treatment in the last 7 days in the area of sampling.
  • •Phototherapy in the last 4 weeks
  • •Active or recurrent serious bacterial, fungal or viral infection at the time of enrollment by patient history, including patients with Human Immunodeficiency Virus (HIV) infection, Hepatitis B and Hepatitis C infection, active or untreated latent tuberculosis.
  • •Female patients of childbearing potential who are pregnant or breast feeding or planning a pregnancy during the duration of the trial and/or not practicing acceptable birth control for the duration of the trial
  • •Known or suspected non-compliance, drug or alcohol abuse,
  • •Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
  • •Previous enrolment into the current study,
  • •Enrolment of the investigator, his/her family members, employees and other dependent persons.

Arms & Interventions

Tape stripping

Experimental

Intervention: Tape stripping (Procedure)

Outcomes

Primary Outcomes

Differences in the transcriptomic profile comparing psoriasis patients with and without induced koebner phenomenon

Time Frame: Day 0, Day 3 (optional), Day 14 (optional)

Transcriptomic profile at all timepoints (reads per 55µm diameter dot)

Secondary Outcomes

  • Characterization of skin mikrobiome(Day 0, Day 3, Day 14)
  • Characterization of involved immune cells in the skin comparing psoriasis patients with and without induced koebner phenomenon(Day 0, Day 3 (optional), Day 14 (optional))
  • Differences in the proteomic profile comparing psoriasis patients with and without induced koebner phenomenon(Day 0, Day 3 (optional), Day 14 (optional))

Investigators

Sponsor
Marie-Charlotte Brüggen
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Marie-Charlotte Brüggen

Prof. Dr. med. PhD

University of Zurich

Similar Trials